Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aidan C A Tomlinson

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Current Opinion in Structural Biology|February 27, 2025
The "three body solution": Structural insights into molecular gluesAidan C A Tomlinson, John E Knox, Luc Brunsveld, et al.
Nature Communications|November 25, 2017
Receptor-binding loops in alphacoronavirus adaptation and evolutionAlan H M Wong, Aidan C A Tomlinson, Dongxia Zhou, et al.
Journal of Medicinal Chemistry|March 8, 2025
Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted CancersJames Cregg, Anne V Edwards, Stephanie Chang, et al.
Cancer Discovery|June 22, 2026
Selective Inhibition of KRASG13C Reveals an Increased Dependence on Wild-Type RAS Isoforms in Codon 13 RAS-Mutant CancersKyle J Seamon, Yongxian Zhuang, Yu Chi Yang, et al.
Journal of Medicinal Chemistry|February 24, 2025
Discovery of Elironrasib (RMC-6291), a Potent and Orally Bioavailable, RAS(ON) G12C-Selective, Covalent Tricomplex Inhibitor for the Treatment of Patients with RAS G12C-Addicted CancersJames Cregg, Kristof Pota, Aidan C A Tomlinson, et al.
Journal of Medicinal Chemistry|December 19, 2022
Discovery of RMC-5552, a Selective Bi-Steric Inhibitor of mTORC1, for the Treatment of mTORC1-Activated TumorsG Leslie Burnett, Yu C Yang, James B Aggen, et al.
Cancer Discovery|April 9, 2024
Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven CancersJingjing Jiang, Lingyan Jiang, Benjamin J Maldonato, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Current Opinion in Structural Biology|February 27, 2025
The "three body solution": Structural insights into molecular gluesAidan C A Tomlinson, John E Knox, Luc Brunsveld, et al.
Nature Communications|November 25, 2017
Receptor-binding loops in alphacoronavirus adaptation and evolutionAlan H M Wong, Aidan C A Tomlinson, Dongxia Zhou, et al.
Journal of Medicinal Chemistry|March 8, 2025
Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted CancersJames Cregg, Anne V Edwards, Stephanie Chang, et al.
Cancer Discovery|June 22, 2026
Selective Inhibition of KRASG13C Reveals an Increased Dependence on Wild-Type RAS Isoforms in Codon 13 RAS-Mutant CancersKyle J Seamon, Yongxian Zhuang, Yu Chi Yang, et al.
Journal of Medicinal Chemistry|February 24, 2025
Discovery of Elironrasib (RMC-6291), a Potent and Orally Bioavailable, RAS(ON) G12C-Selective, Covalent Tricomplex Inhibitor for the Treatment of Patients with RAS G12C-Addicted CancersJames Cregg, Kristof Pota, Aidan C A Tomlinson, et al.
Journal of Medicinal Chemistry|December 19, 2022
Discovery of RMC-5552, a Selective Bi-Steric Inhibitor of mTORC1, for the Treatment of mTORC1-Activated TumorsG Leslie Burnett, Yu C Yang, James B Aggen, et al.
Cancer Discovery|April 9, 2024
Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven CancersJingjing Jiang, Lingyan Jiang, Benjamin J Maldonato, et al.
Pageof 1